Viking Therapeutics (NASDAQ: VKTX) presented exploratory Phase 2 VENTURE data for subcutaneous VK2735 at ObesityWeek 2025 showing improvements in cardiometabolic status after 13 weeks.
Key findings: 78% of VK2735-treated prediabetic patients shifted to normoglycemic vs 29% placebo (p=0.0008); 68% of patients with metabolic syndrome no longer met criteria vs 38% placebo (p=0.02). Up to 14.7% mean body-weight reduction and up to 88% achieved ≥10% weight loss; most drug-related TEAEs (92%) were mild or moderate. Viking also highlighted the Phase 3 VANQUISH-1 trial design.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.